An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis.

Trial Profile

An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Mercaptamine (Primary)
  • Indications Cystic fibrosis
  • Focus First in man; Pharmacokinetics
  • Most Recent Events

    • 06 Apr 2017 This trial has been discontinued in UK (End date:2015-03-06) as per European Clinical Trials Database record.
    • 24 Jun 2016 According to a NovaBiotics media release, data this trial was presented at the ASM Microbe conference.
    • 14 Jun 2015 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top